Patents by Inventor Jeffrey William Raggon

Jeffrey William Raggon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7521456
    Abstract: The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: April 21, 2009
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Douglas John Meldrum Allen, Timothy Norris, Jeffrey William Raggon, Dinos Paul Santafianos, Ravi Mysore Shanker
  • Publication number: 20040102463
    Abstract: The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.
    Type: Application
    Filed: November 17, 2003
    Publication date: May 27, 2004
    Applicant: OSI Pharmaceuticals, Inc.
    Inventors: Douglas John Meldrum Allen, Timothy Norris, Jeffrey William Raggon, Dinos Paul Santafianos, Ravi Mysore Shanker
  • Patent number: 6706721
    Abstract: The present invention relates to the anhydrous and hydrate forms of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate. The invention also relates to pharmaceutical compositions containing N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and to methods of treating hyperproliferative disorders, such as cancer, by administering N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: March 16, 2004
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Douglas John Meldrum Allen, Timothy Norris, Jeffrey William Raggon, Dinos Paul Santafianos, Ravi Mysore Shanker
  • Patent number: 6388127
    Abstract: The present invention relates to a process for preparing a compound of the formula wherein b, Y and R3 are defined as above, useful for preparing novel aralkyl and aralkylidene heterocyclic lactams and imides which are selective agonists and antagonists of serotonin 1 (5-HT1) receptors.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: May 14, 2002
    Assignee: Pfizer INC
    Inventors: George Joseph Quallich, Jeffrey William Raggon, Paul D. Hill